References
- 1. Riazi K., Azhari H., Charette J.H. et al. (2022) The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol., 7(9): 851–861. doi: 10.1016/S2468-1253(22)00165-0.
- 2. Quek J., Chan K.E., Wong Z.Y. et al. (2023) Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroent. Hepatol., 8: 20–30.
- 3. Yin X., Guo X., Liu Z. et al. (2023) Advances in the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease. Int. J. Mol. Sci., 24: 2844. doi: 10.3390/ijms24032844.
- 4. Thomsen K.L., Eriksen P.L., Kerbert A.J. et al. (2023). Role of ammonia in NAFLD: an unusual suspect. JHEP Rep., 5(7): 100780. doi: 10.1016/j.jhepr.2023.100780.
- 5. Bedogni G., Bellentani S., Miglioli L. et al. (2006) The Fatty Liver Index: A simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol., 6: 33. doi: 10.1186/1471-230X-6-33.
- 6. Kotronen A., Peltonen M., Hakkarainen A. et al. (2009) Prediction of Non-Alcoholic Fatty Liver Disease and Liver Fat Using Metabolic and Genetic Factors. Gastroenterol., 137: 865–872.
- 7. Lee J.H., Kim D., Kim H.J. et al. (2010) Hepatic steatosis in-dex: a simple screening tool reflecting nonalcoholicfatty liver disease. Dig. Liver Dis., 42: 503–550.
- 8. Poynard T., Ratziu V., Naveau S. et al. (2005) The diagnosticvalue of biomarkers (SteatoTest) for the prediction ofliver steatosis. Comp. Hepatol., 4: 1–10.
- 9. Rojas Á., García-Lozano M.R., Gil-Gómez A. et al. (2022) Glutaminolysis-ammonia-urea Cycle Axis, Non-alcoholic Fatty Liver Disease Progression and Development of Novel Therapies. J. Clin. Transl. Hepatol., 10(2): 356–362.
- 10. Azagra M., Pose E., De Chiara F. et al. (2022) Ammonium quantification in human plasma by proton nuclear magnetic resonance for staging of liver fibrosis in alcohol‐related liver disease and nonalcoholic fatty liver disease. NMR Biom., 35: e4745.
- 11. Balcar L., Krawanja J., Scheiner B. et al. (2023) Impact of ammonia levels on outcome in clinically stable outpatients with advanced chronic liver disease. JHEP Rep., 5(4): 100682. doi: 10.1016/j.jhepr.2023.100682.
- 12. Kjærgaard A.C.D., Mikkelsen C.W., Wernberg L.L. et al. (2021) Cognitive dysfunction in non-alcoholic fatty liver disease-current knowledge, mechanisms and perspectives. J. Clin. Med., 10: 673. doi: 10.3390/jcm10040673.
- 13. Canbay A., Sowa J.P. (2019) L-Ornithine L-Aspartate (LOLA) as a Novel Approach for Therapy of Non-alcoholic Fatty Liver Disease. Drugs, 79(Suppl. 1): 39–44.
- 14. Grüngreiff K., Lambert-Baumann J. (2001) Efficacy of L-ornithin-L-aspartate-granules in chronic liver diseases. Die Medizinische Welt, 52(7): 219–226.
- 15. Butterworth R.F., Canbay A. (2018) Hepatoprotection by L-ornithine L-aspartate in non-alcoholic fatty liver disease. Digest. Dis., 37(1): 63–68. doi: 10.1159/000491429.
- 16. Ermolova T., Ermolov S. (2018) Correction of intrahepatic microcirculation disorders by L-ornithine-L-aspartate at the chronic liver diseases patients. J. Hepatol., 68: S585–S586.